Mathematical Model Estimates False-Negative Rate for COVID-19 Tests

Researchers have developed a mathematical model to estimate false-negative rate for COVID-19 tests.

The mathematical means of assessing tests’ false-negative rate develop by researchers at the Beth Israel Deaconess Medical Center (BIDMC Boston, MA, USA) allows an apples-to-apples comparison of the various assays' clinical sensitivity. As of June 2020, the U.S. Food and Drug Administration (FDA) had granted emergency use authorization for more than 85 different viral DNA test kits - or assays - each with widely varying degrees of sensitivity and unknown rates of accuracy. However, with no existing gold standard test for the novel coronavirus, there's little data on which to judge these various tests' usefulness to municipalities' efforts to safely re-open for business.


COVID test results are usually reported as simply positive or negative. However, positive individuals can harbor radically different amounts of virus, or viral load, depending on how long they've been infected or how severe their symptoms are. In fact, viral load can vary as much as a hundred million-fold among individuals. Using data from more than 27,000 tests for COVID-19 performed at Beth Israel Lahey Health hospital sites from March 26 to May 2, 2020, researchers first demonstrated that viral loads can be dependably reported. Next, the researchers estimated the clinical sensitivity and the false-negative rate first for the in-house test - which was among the first to be implemented nationwide and considered among the best in class. Analyzing repeat test results for the nearly 5,000 patients who tested positive allowed the researchers to determine that the in-house test provided a false negative in about 10% of cases, giving the assay a clinical sensitivity of about 90%.

To estimate the accuracy of other assays, the team based their calculations on each tests' limit of detection, or LoD, defined as the smallest amount of viral DNA detectable that a test will catch 95% or more of the time. The researchers demonstrated that the limit of detection can be used as a proxy to estimate a given assay's clinical sensitivity. By the team's calculations, an assay with a limit of detection of 1,000 copies viral DNA per mL is expected to detect just 75% of patients with COVID-19, providing one out of every four people with a false-negative. The team also showed that one test available today misses as many as one in three infected individuals, while another may miss up to 60% of positive cases. While not every COVID positive patient missed by sensitive PCR and antigen detection tests will be infectious to others, some will, the researchers note.

"For getting back to business as usual, we all agree we've got to massively ramp up testing to figure out who's negative and who's infectious - but that's only going to work optimally if you can catch all the positive cases," said co-corresponding author James E. Kirby, MD, Director of the Clinical Microbiology Laboratories at BIDMC. "We found that clinical sensitivities vary widely, which has clear implications for patient care, epidemiology and the social and economic management of the ongoing pandemic."
"These results are especially important as we transition from testing mostly symptomatic individuals to more regular screening across the community," said co-corresponding author Ramy Arnaout, MD, DPhil, Associate Director of the Clinical Microbiology Laboratories at BIDMC. "How many people will be missed - the false negative rate - depends on which test is used. With our model, we are better informed to ask how likely these people are to be infectious."


Related Links:
Beth Israel Deaconess Medical Center